A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Anal Cancer
Interventions
BIOLOGICAL

Treatment

ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.

DRUG

5FU

1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days

DRUG

Mitomycin

10 mg/m2, day 1 and 29 (day 29 can be + 7 days)

RADIATION

IMRT

54 Gy in 30 fractions at 1.8 Gy per fraction.

Trial Locations (3)

10467

Montefiore Medical Center, New York

02903

Rhode Island Hospital, Providence

02906

The Miriam Hospital, Providence

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Rhode Island Hospital

OTHER

collaborator

The Miriam Hospital

OTHER

lead

Brown University

OTHER